Literature DB >> 22938424

Predictive role of ERCC1 and XPD genetic polymorphisms in survival of Chinese non-small cell lung cancer patients receiving chemotherapy.

Zhen-Yong Zhang1, Xin Tian, Rong Wu, Yuan Liang, Xue-Ying Jin.   

Abstract

AIM: There is increasing evidence that ERCC1 and XPD have roles in response to chemotherapy among patients with NSCLC, but the results are conflicting. Therefore, we conducted the present prospective study in a Chinese population.
METHODS: A total of 632 primary NSCLC patients were included, followed-up from May 2006 to May 2011. Polymorphisms were detected by real time PCR with TaqMan probse, using genomic DNA extracted from peripheral blood samples. The Cox regression model was used to analyze the hazard ratios (HR) for ERCC1 and XPD.
RESULTS: The median time of follow-up was 31.6 months. Our results showed the ERCC1 118 T/T(HR=1.65, 95% CI=1.17-2.43) and XPD 751 Gln/ Gln genotypes (HR=1.52, 95%CI=1.04-2.08) were associated with an increased risk of death from NSCLC. Moreover, the ERCC118 T allele and XPD 751 Gln allele genotypes had a more higher risk of death from NSCLC among both ex-smokers and current smokers.
CONCLUSION: In summary, ERCC1 and XPD gene polymorphisms might provide better prognostic predictive information for NSCLC patients in Chinese populations, with smoking possibly interacting with the genotypes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22938424     DOI: 10.7314/apjcp.2012.13.6.2583

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  12 in total

1.  Polymorphisms in ERCC1 gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients.

Authors:  Xin Zhao; Zhiqiang Zhang; Yan Yuan; Xiaomei Yuan
Journal:  Tumour Biol       Date:  2014-05-24

2.  Polymorphisms in ERCC1 and ERCC2/XPD genes and carcinogen DNA adducts in human lung.

Authors:  Mi-Sun Lee; Chen-yu Liu; Li Su; David C Christiani
Journal:  Lung Cancer       Date:  2015-05-11       Impact factor: 5.705

Review 3.  The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.

Authors:  Yanlong Yang; Lei Xian
Journal:  Tumour Biol       Date:  2013-12-13

4.  ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin.

Authors:  M Tiseo; P Bordi; B Bortesi; L Boni; C Boni; E Baldini; F Grossi; F Recchia; F Zanelli; G Fontanini; N Naldi; N Campanini; C Azzoni; C Bordi; A Ardizzoni
Journal:  Br J Cancer       Date:  2013-04-02       Impact factor: 7.640

Review 5.  Predictive value of XPD polymorphisms on platinum-based chemotherapy in non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Mantang Qiu; Xin Yang; Jingwen Hu; Xiangxiang Ding; Feng Jiang; Rong Yin; Lin Xu
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

Review 6.  A Significant Statistical Advancement on the Predictive Values of ERCC1 Polymorphisms for Clinical Outcomes of Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: An Updated Meta-Analysis.

Authors:  Yali Han; Jie Liu; Meili Sun; Zongpu Zhang; Chuanyong Liu; Yuping Sun
Journal:  Dis Markers       Date:  2016-01-21       Impact factor: 3.434

7.  A genetic variant in long non-coding RNA MALAT1 associated with survival outcome among patients with advanced lung adenocarcinoma: a survival cohort analysis.

Authors:  Jian-Zhong Wang; Jing-Jun Xiang; Li-Ge Wu; Yan-Sen Bai; Zhuo-Wang Chen; Xiang-Qian Yin; Qing Wang; Wen-Hao Guo; Ying Peng; Huan Guo; Ping Xu
Journal:  BMC Cancer       Date:  2017-03-03       Impact factor: 4.430

8.  Predictive Value of Single Nucleotide Polymorphisms of ERCC1, XPA, XPC, XPD and XPG Genes, Involved in NER Mechanism in Patients with Advanced NSCLC Treated with Cisplatin and Gemcitabine.

Authors:  Radosław Mlak; Paweł Krawczyk; Iwona Homa-Mlak; Tomasz Powrózek; Marzanna Ciesielka; Piotr Kozioł; Janusz Milanowski; Teresa Małecka-Massalska
Journal:  Pathol Oncol Res       Date:  2018-07-31       Impact factor: 3.201

9.  Polymorphisms in XPD gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients: a meta-analysis of 24 studies.

Authors:  Qin Qin; Chi Zhang; Xi Yang; Hongcheng Zhu; Baixia Yang; Jing Cai; Hongyan Cheng; Jianxin Ma; Jing Lu; Liangliang Zhan; Jia Liu; Zheming Liu; Liping Xu; Xinchen Sun
Journal:  PLoS One       Date:  2013-11-15       Impact factor: 3.240

10.  ERCC1 single nucleotide polymorphism C8092A, but not its expression is associated with survival of esophageal squamous cell carcinoma patients from Fujian province, China.

Authors:  Wan-Hua Chen; Pei-Ling Xin; Qun-Xiong Pan; Ya-Yun Chen; Cong-Ren Wang; Zhi-Shan Zhang; Yi-Feng Chen; Chao-Yang Zhang; Wen-Jie Cai
Journal:  PLoS One       Date:  2014-09-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.